Dermatology News: 2007.4

• 2007.4(10) Photoprotective effects of green tea polyphenols
  Non-melanoma skin cancer is the most common malignancy in humans and is equivalent to the incidence of malignancies in all other organs combined in the United States. Current methods of prevention depend on sunscreens in humans, efficacy of which is largely undetermined for non-melanoma skin cancers. Green tea polyphenols have the greatest effect with respect to...   |   Read more ...



• 2007.4(9) Severe psoriasis treated with a new macrolide: everolimus
  Psoriasis is an immune-mediated disease with a chronic relapsing course, and the particularly severe forms that are refractory to traditional therapies are often difficult to manage. Everolimus...   |   Read more ...



• 2007.4(8) An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema
  Treatment options for moderate-to-severe atopic eczema are limited. Although methotrexate (MTX) is a widely used and effective treatment for psoriasis, there have been no previous prospective trials of its use in refractory atopic eczema...   |   Read more ...



• 2007.4(7) Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma
  Patients with metastatic skin disease in malignant melanoma can be difficult to treat effectively, often requiring repeated treatments with different modalities in an attempt to control their disease. Treatment of nonsurgically resectable melanoma deposits is unsatisfactory, as they are often multiple and recurring...   |   Read more ...



• 2007.4(6) A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity
  Infliximab, an antitumour necrosis factor-a chimeric monoclonal antibody, is effective for the treatment of severe psoriasis. While the induction of antinuclear antibodies (ANA) and antidouble-stranded-DNA antibodies (anti-dsDNA-ab) is frequently observed in patients with rheumatoid arthritis and Crohn disease receiving infliximab, the incidence of induced biological and clinical autoimmunity remains unknown in the context of psoriasis...   |   Read more ...



• 2007.4(5) The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study
  While many studies have demonstrated the efficacy and safety of tacrolimus ointment in the treatment of atopic dermatitis (AD), only a few have investigated the effects of tacrolimus on inflammatory cells and their cytokine gene expression in patients with AD...   |   Read more ...



• 2007.4(4) Atopic dermatitis in adolescent boys is associated with greater psychological morbidity compared with girls of the same age: the Young-HUNT study
  Having atopic dermatitis (AD) as well as other chronic diseases is often associated with reduced mental health. Adolescents with AD are thought to be especially vulnerable, but few studies have included an ample number of young people...   |   Read more ...



• 2007.4(3) Psoriasis: a possible risk factor for development of coronary artery calcification
  Psoriasis: a possible risk factor for development of coronary artery calcification   |   Read more ...



• 2007.4(2) Contact dermatitis to a canine anti-dandruff shampoo
  A 40-year-old teacher presented after her third episode of acute facial oedema within 4 months. Each episode occurred 1-2 days after visiting her mother's house. Patch testing showed positive reactions to miconazole and econazole nitrate...   |   Read more ...



• 2007.4(1) Facial Sweet's syndrome mimicking rosacea fulminans
  A 36-year-old man presented with a non-pruritic, erythematous facial rash with peri-oral and peri-orbital sparing. The initial clinicopathological diagnosis was rosacea fulminans, which was treated with 25 mg oral prednisolone and cephalexin...   |   Read more ...

    Current Year Archive:   Dermatology News 2007   |   Main Archive:   Dermatology News  

The Derm News service provided by the Editorial Consultants of Skin Therapy Letter^© and its founding editor Dr. Stuart Maddin.